Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. more
Time Frame | TERN | Sector | S&P500 |
---|---|---|---|
1-Week Return | 6.08% | -3.72% | -0.05% |
1-Month Return | 22.46% | -1.85% | 2.75% |
3-Month Return | -25.82% | -11.4% | 7.4% |
6-Month Return | -12.31% | -4.41% | 10.47% |
1-Year Return | 7.55% | 4.13% | 27.57% |
3-Year Return | 23.54% | 0.3% | 29.56% |
5-Year Return | -62.04% | 36.62% | 89.3% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | 1.00M | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 195.00K | 394.00K | 512.00K | 1.03M | 881.00K | [{"date":"2019-12-31","value":18.9,"profit":true},{"date":"2020-12-31","value":38.18,"profit":true},{"date":"2021-12-31","value":49.61,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":85.37,"profit":true}] |
Gross Profit | (195.00K) | (394.00K) | 1.00M | (1.03M) | (881.00K) | [{"date":"2019-12-31","value":-19.5,"profit":false},{"date":"2020-12-31","value":-39.4,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-103.2,"profit":false},{"date":"2023-12-31","value":-88.1,"profit":false}] |
Gross Margin | (Infinity%) | (Infinity%) | 100.00% | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 70.20M | 37.02M | 50.86M | 62.03M | 102.56M | [{"date":"2019-12-31","value":68.45,"profit":true},{"date":"2020-12-31","value":36.1,"profit":true},{"date":"2021-12-31","value":49.59,"profit":true},{"date":"2022-12-31","value":60.48,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (70.20M) | (37.02M) | (49.86M) | (62.03M) | (102.56M) | [{"date":"2019-12-31","value":-7019700000,"profit":false},{"date":"2020-12-31","value":-3702500000,"profit":false},{"date":"2021-12-31","value":-4986000000,"profit":false},{"date":"2022-12-31","value":-6202900000,"profit":false},{"date":"2023-12-31","value":-10255800000,"profit":false}] |
Total Non-Operating Income/Expense | 2.56M | (2.68M) | 380.00K | 4.15M | 25.49M | [{"date":"2019-12-31","value":10.05,"profit":true},{"date":"2020-12-31","value":-10.51,"profit":false},{"date":"2021-12-31","value":1.49,"profit":true},{"date":"2022-12-31","value":16.29,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (68.84M) | (39.76M) | (49.65M) | (59.99M) | (89.97M) | [{"date":"2019-12-31","value":-6883900000,"profit":false},{"date":"2020-12-31","value":-3975800000,"profit":false},{"date":"2021-12-31","value":-4965000000,"profit":false},{"date":"2022-12-31","value":-5998700000,"profit":false},{"date":"2023-12-31","value":-8997100000,"profit":false}] |
Income Taxes | (20.00K) | 813.00K | 508.00K | 358.00K | 239.00K | [{"date":"2019-12-31","value":-2.46,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":62.48,"profit":true},{"date":"2022-12-31","value":44.03,"profit":true},{"date":"2023-12-31","value":29.4,"profit":true}] |
Income After Taxes | (68.82M) | (40.57M) | (50.16M) | (60.34M) | (90.21M) | [{"date":"2019-12-31","value":-6881900000,"profit":false},{"date":"2020-12-31","value":-4057100000,"profit":false},{"date":"2021-12-31","value":-5015800000,"profit":false},{"date":"2022-12-31","value":-6034500000,"profit":false},{"date":"2023-12-31","value":-9021000000,"profit":false}] |
Income From Continuous Operations | (68.82M) | (40.57M) | (50.16M) | (60.34M) | (90.21M) | [{"date":"2019-12-31","value":-6881900000,"profit":false},{"date":"2020-12-31","value":-4057100000,"profit":false},{"date":"2021-12-31","value":-5015800000,"profit":false},{"date":"2022-12-31","value":-6034500000,"profit":false},{"date":"2023-12-31","value":-9021000000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (68.82M) | (40.57M) | (50.16M) | (60.34M) | (90.21M) | [{"date":"2019-12-31","value":-6881900000,"profit":false},{"date":"2020-12-31","value":-4057100000,"profit":false},{"date":"2021-12-31","value":-5015800000,"profit":false},{"date":"2022-12-31","value":-6034500000,"profit":false},{"date":"2023-12-31","value":-9021000000,"profit":false}] |
EPS (Diluted) | - | (30.94) | (2.34) | (1.83) | (1.27) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-3094,"profit":false},{"date":"2021-12-31","value":-234,"profit":false},{"date":"2022-12-31","value":-183,"profit":false},{"date":"2023-12-31","value":-127,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
TERN | |
---|---|
Cash Ratio | 32.67 |
Current Ratio | 32.99 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
TERN | |
---|---|
ROA (LTM) | -19.23% |
ROE (LTM) | -28.28% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
TERN | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.04 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.96 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
TERN | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 302.64 |
P/B | 1.57 |
Price/FCF | NM |
EV/R | 337.47 |
EV/Ebitda | NM |
Terns Pharmaceuticals Inc (TERN) share price today is $6.98
Yes, Indians can buy shares of Terns Pharmaceuticals Inc (TERN) on Vested. To buy Terns Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TERN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Terns Pharmaceuticals Inc (TERN) via the Vested app. You can start investing in Terns Pharmaceuticals Inc (TERN) with a minimum investment of $1.
You can invest in shares of Terns Pharmaceuticals Inc (TERN) via Vested in three simple steps:
The 52-week high price of Terns Pharmaceuticals Inc (TERN) is $11.4. The 52-week low price of Terns Pharmaceuticals Inc (TERN) is $4.32.
The price-to-earnings (P/E) ratio of Terns Pharmaceuticals Inc (TERN) is
The price-to-book (P/B) ratio of Terns Pharmaceuticals Inc (TERN) is 1.57
The dividend yield of Terns Pharmaceuticals Inc (TERN) is 0.00%
The market capitalization of Terns Pharmaceuticals Inc (TERN) is $571.64M
The stock symbol (or ticker) of Terns Pharmaceuticals Inc is TERN